Please enter your login details

You can also sign in with your Sowetan LIVE
and Sport LIVE account details.
   Sign Up   Forgot password?

Sign in with:

 
  • All Share : 40687.82
    DOWN -0.77%
    Top 40 : 3382.36
    DOWN -0.63%
    Financial 15 : 11051.75
    DOWN -1.70%
    Industrial 25 : 46788.93
    DOWN -0.48%

  • ZAR/USD : 9.9456
    DOWN -0.54%
    ZAR/GBP : 15.5766
    DOWN -0.35%
    ZAR/EUR : 13.3261
    DOWN -0.46%
    ZAR/JPY : 0.1046
    DOWN -0.08%
    ZAR/AUD : 9.4708
    DOWN -0.19%

  • Gold : 1372.7500
    UP 0.34%
    Platinum : 1433.7000
    DOWN -0.37%
    Silver : 21.7593
    UP 0.44%
    Palladium : 705.5000
    DOWN -0.21%
    Brent Crude Oil : 106.350
    UP 0.31%

  • All data is delayed by 15 min. Data supplied by I-Net Bridge
    Hover cursor over this ticker to pause.

Wed Jun 19 16:32:05 SAST 2013

GlaxoSmithKline recalls Grand-Pa headache powders

Sapa | 26 July, 2012 13:31

GlaxoSmithKline, the company that makes Grand-Pa, is recalling some batches of the headache medicine in South Africa after some were found to be counterfeit.

"The affected product should not be used as counterfeit medicines are not subject to the rigorous safety and quality checks by GSK, as is the case for genuine Grand-Pa powders," the company said in a statement on Thursday.

The counterfeit products are being sold as Grand-Pa Powders, 38-count, and have batch numbers 309339 and 314020.

The counterfeit powder is being sold in packaging that has subtle differences from the genuine product. The fakes have spelling errors in the text on the package. For example, the word "koors" is misspelled "kors".

The company said it was testing the counterfeit powder at its laboratories in the United Kingdom to establish the contents of the fake product.

GSK said it was voluntarily recalling its own products bearing those batch numbers in an effort to protect consumers.

It asks that consumer call its help line, 0800-118274, if they have queries or need assistance.

SHARE YOUR OPINION

If you have an opinion you would like to share on this article, please send us an e-mail to the Times LIVE iLIVE team. In the mean time, click here to view the Times LIVE iLIVE section.